We're delighted to receive o2h's Kickstarter award this year. Our primary mission is developing therapeutics to safely target processes shared by many neurodegenerative diseases as well as chronic cognitive, fatigue, and pain disorders. o2h's support of this mission is truly inspiring, and the expertise of their chemistry and biology teams serves as a vital catalyst for our first two discovery projects.

We’re honored to receive o2h’s Kickstarter Award, a meaningful validation of our novel program addressing debilitating symptoms of Parkinson’s Disease. Psy's collaboration with o2h's superb chemistry team will further accelerate this high-impact program’s path to the clinic and advance our broader mission to deliver transformative treatments to patients in need.

The kickstarter competition was transformative for Sevenless. We were able to effectively put 10 full time FTEs on our lead optimization program, which delivered novel chemistry ahead of schedule. The progress was outstanding and the o2h team a pleasure to work with. Kickstarter did for us exactly as it’s name suggests. We are now looking to move a drug candidate forward through IND enabling studies and towards Phase I clinical trials.

Protai is excited to be partnering with o2h's chemistry in order to accelerate our proteomin biomarker-led drug discoveries and development activities. Protai is excited to be partnering with o2h's chemistry in order to accelerate our proteomin biomarker-led drug discoveries and development activities. Protai is excited to be partnering with o2h's chemistry in order to accelerate our proteomin biomarker-led drug discoveries and development activities. Protai is excited to be partnering with o2h's chemistry in order to accelerate our proteomin biomarker-led drug discoveries and development activities. Protai is excited to be partnering with o2h's chemistry in order to accelerate our proteomin biomarker-led drug discoveries and development activities.

The Kickstarter will enable us to thoroughly explore our nascent SAR and advance our lead program more rapidly.

The o2h Kickstarter competition promises to be an excellent scheme allowing early-stage companies like ours to get access to synthetic chemistry.

We have been fortunate enough to work with the outstanding o2h Kickstarter team, which has enabled us to move rapidly through our compound screening programme in an exceptionally cost-effective fashion. The O2H team bring great depth of expertise and experience of the pharmaceutical sector, with a strong understanding of our specific needs. The whole O2H team has worked efficiently and diligently, with high quality end results that are enabling us to reach for our long-terms goals to bring new therapeutics to cancer patients.

At Cellestial, our goal is to maximise patient benefit that our treatments can offer. Small molecule therapeutics remain the most scalable form of treatment modality, meaning that more people around the world can benefit from them. We are proud to partner with o2h to expand our pipeline of astrocyte-protective small molecule drugs. The expertise provided both on the conceptual planning stage as well as the synthesis efficiency is world-class.

Running a chemistry program is always a challenging sell to investors. The o2h kickstarter award did several things. It defrayed the cost of the program. It gave us access to a large team of skilled synthetic chemists. It allowed us to partner with experienced medicinal chemists. Finally o2hs review of our proposed program helped validate it and unlock investor funding.

We are deeply grateful to the o2h Kickstarter program for their invaluable support in advancing our small molecule discovery efforts. This partnership has enabled us to expand our compound portfolio and accelerate the lead optimization phase of our lead program. Support from initiatives like o2h Kickstarter plays a crucial role in helping early-stage biotech companies translate scientific innovation into tangible therapeutic opportunities.

The Kickstarter Award has been pivotal for our development progress. Medchem can be expensive and challenging for early-stage biotechs, but we are now enjoying the momentum this high-quality chemistry programme brings to our lead optimisation. We had heard good things about the Kickstarter before we applied and I am happy to pass on that positivity from our own experience.

The Kickstarter provides vital access to chemists with the skills and knowledge to deliver on the promise of our technology.

I am thrilled that Five Alarm Bio has been awarded the Kickstarter program. We will benefit from the extensive knowledge and enthusiasm of the o2h leadership and laboratory scientists.

The Kickstarter Award allowed us to cost-effectively advance our lead program without sacrificing on quality. The professionalism and productivity of the o2h team was exceptional and I would recommend them to anyone looking for chemistry support.

o2h’s Kickstarter Award has substantially accelerated our lead-series expansion plans, thanks to a professional team that has been over-delivering on some rather challenging and exciting chemistry.